Regulators Reassure On AZ Vaccine Safety After Rare Side Effect Deemed Plausible
Vaccine Faces Global Confidence Test
The EMA and MHRA issue parallel safety updates on the vaccine, with the UK offering an alternative of the Pfizer/BioNTech or Moderna vaccines to the under 30s.
You may also be interested in...
J&J and Pfizer should benefit from India’s unusual move to grant accelerated approvals minus a prior local bridging study for COVID-19 vaccines granted emergency use authorizations by certain regulators or on the WHO’s emergency use list. But while this seems like a prelude to permitting private sales, where will the supplies come from?
While preclinical data show boosters to MRNA-1273 can reduce the threat of viral variants, the biotech also told investors it sees no link between its vaccine and thrombotic episodes.
The CDC and FDA recommended a pause on dosing of J&J's one-shot vaccine. Pfizer/BioNTech's vaccine showed signs of lower efficacy against the B.1.351 variant, but a prominent expert called the data "misleading." Gilead halted its Phase III study of Veklury in non-hospitalized, high-risk patients. And Rigel's Tavalisse may have a shot in the sickest COVID-19 patients despite the small size of a Phase II study.